FIELD: chemistry.
SUBSTANCE: invention provides an amorphous solid dispersion comprising a taxane or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable polymer, and a pharmaceutically acceptable surfactant, which increases solubility. Method of producing a solid dispersion is also disclosed.
EFFECT: present invention also provides a tablet characterised by good solubility, bioavailability and stability, which comprises an amorphous solid dispersion, an intragranular excipient and an extragranular excipient.
29 cl, 9 dwg, 16 tbl, 25 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ORAL COMPOSITIONS OF CARDIAC SARCOMERE INHIBITORS | 2020 |
|
RU2823999C2 |
| ANTI-TUBERCULOSIS STABLE PHARMACEUTICAL COMPOSITION IN A FORM OF A COATED TABLET COMPRISING GRANULES OF ISONIAZID AND GRANULES OF RIFAPENTINE AND ITS PROCESS OF PREPARATION | 2014 |
|
RU2682178C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CYSTIC FIBRIOSIS | 2019 |
|
RU2822220C2 |
| METHODS OF TREATING SOLID TUMORS | 2017 |
|
RU2737934C2 |
| ANTI-TUBERCULOSIS STABLE PHARMACEUTICAL COMPOSITION IN FORM OF DISPERSIBLE TABLET CONTAINING GRANULATED ISONIAZID AND GRANULATED RIFAPENTINE, AND METHOD FOR PREPARING IT | 2014 |
|
RU2694056C2 |
| PHARMACEUTICAL PREPARATIONS WITH FIXED COMBINATION OF ANALGESIC AND ANTISPASMODIC AGENTS DOSES | 2015 |
|
RU2704613C2 |
| METHODS FOR TREATMENT OF LUNG DISORDERS | 2018 |
|
RU2773750C2 |
| PHARMACEUTICAL COMPOSITIONS WITH CDC7 INHIBITOR | 2019 |
|
RU2810927C2 |
| SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING INTEGRASE INHIBITOR | 2010 |
|
RU2602865C2 |
| SOLID DISPERSIONS | 2016 |
|
RU2694832C2 |
